Just a crazy observation from an old trader - if last week's whippy action continues, I consider it an extremely bullish signal. Just watch it bounce from the 19's.
Contemplated selling, but I will hang in there. I agree with comments that there looks to be someone large getting out, but that is not the problem. The problem is no one is here buying. The price dropped 50 cents on 200k volume this morning.
RSI is the lowest is has been. Stochastic indicates oversold. MACD is at a low...on and on. Eventually the market is going to wake up and buying pressure should take it up as quick as it came down...probably quicker...
I admit I came in early on this one though...oh well, tough to call the tops and the bottoms as a retail...
I guess my point is that I'm not abandoning this stock. Just waiting.
when the trolls appear, the end to the selling is near!
Already drop $6 since earning report, something looks very wrong.
Lets see if the company releases any good news to bring investors back aboard. Maybe a positive update on one of the clinical trials or possibly some collaboration update with one of the major partners! Something will happen to help get back the 20% lost since earning announcement date ($5 decrease in share price)!
YIKES. Thank God I moved half of my position to OMER. This is looking played out.
EXEL has done great for me, I'm not going to complain. I did exit half my position at 21, if it gets too low, I'll buy them back.
Relax some people selling and smart ones thinking long term. Hang onto ur stocks and accumulate. This is a great company to own. Don't doubt exel. It will double ur $$
I strongly suspect we won't see $22 today!
I wonder if today's action (down in an up day) is due to options expiration?
Options traders trying to get it to close under $20. Don't sell.
Just a little sideways movement guys - I am in...
Finally, it may make sense. I've been wracking my brain to figure out why EXEL may not file for first line. It was a bargining chip that brough in BMS.
BMS has a combo P3 with Nivolumab and Ipilimumab vs. Sunitinib and if Cabozantinib took first line, that would through a wrench in their P3 trial that is set to have data 2H 2019. (CheckMate 214) It's finished recruiting.
BMS also has a trial similar to what I susgested the FDA may want for cabo which people did not like. It's (NIVOSWITCH) a OS evaluation of switching to Nivo.
But there it is. The P3 combo trial may have come with a deal that EXEL would not file for first line with cabo so BMS can knock out Novartis and get extra sells since both Ipilimumab and Nivo is BMS owned.
My portfolio lost so much today
Well.....I need a drink.
Sam you gave me my laugh for today!!
If you survived the Great Recession, you can survive this and more!
Relax everyone. There's no bad news. Today is due to Trump. Tomorrow and Friday it will blow over and EXEL will be back over 21. All the news was very positive during earnings only 2 weeks and 3 days ago. Smart institutions probably picked up shares on the cheap today as numerous catalyst events in the 2nd half of 2017. Wish I had dry powder to add more today. Remember cream always rises to the top and EXEL is one of the best mid cap bio's in the sector (and may have become an attractive buyout candidate at the current sub $20 share price)!!